z-logo
Premium
Role of Cytochrome P4502B6 in Methadone Metabolism and Clearance
Author(s) -
Kharasch Evan D.,
Stubbert Kristi
Publication year - 2013
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.1
Subject(s) - methadone , drug metabolism , metabolic clearance rate , metabolism , pharmacology , cytochrome p450 , cytochrome , medicine , pharmacokinetics , chemistry , drug , biochemistry , enzyme
Methadone N ‐demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4. This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N ‐demethylation and clearance, using the in vivo mechanism‐based CYP2B6 inhibitor ticlopidine, given orally for 4 days. A preliminary clinical investigation with the CYP3A4/5 substrate probe alfentanil established that ticlopidine did not inhibit intestinal or hepatic CYP3A4/5. Subjects received intravenous plus oral (deuterium‐labeled) racemic methadone before and after ticlopidine. Ticlopidine significantly and stereoselectively (S > R) inhibited methadone N ‐demethylation, decreasing plasma metabolite/methadone area under the curve ratios and metabolite formation clearances. Ticlopidine also significantly increased the dose‐adjusted plasma area under the curve for R‐ and S‐methadone by 20% and 60%, respectively, after both intravenous and oral dosing. CYP2B6 inhibition reduces methadone N ‐demethylation and clearance, and alters methadone concentrations, demonstrating an important role for CYP2B6 in clinical methadone disposition.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here